Drug intelligence / Profile preview

EMD-302

Development stage: Preclinical
Lead developer: EmendoBio
Modality: Gene Therapies

Overview

EMD-302 is a gene modulator drug developed by Emendo Biotherapeutics. It is currently in the discovery stage for hyperlipidemias and in earlier development stages for inborn errors of metabolism. Its mechanism of action involves gene modulation, likely utilizing CRISPR gene editing technology, to address genetic conditions. Emendo Biotherapeutics is a CRISPR gene editing company, indicating that EMD-302 is a gene therapy designed for both in-vivo and ex-vivo applications.

Beyond the preview

Go deeper on EMD-302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EMD-302.

Explore the full profile